LRRC32 and gastric cancer: Indeed, Kai Li et al. have shown that neoadjuvant chemotherapy decreased the infiltration of GARP+ Tregs in intratumoral gastric cancer [21] and suggested that GARP could, therefore, represent a marker for therapeutic monitoring and response to treatment.